Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
成都马甲子生物科技
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Chengdu Majiazi Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, and a subsidiary of Sichuan Zitongpalace Pharmaceutical. The company specializes in the research and development of innovative Chinese medicines (TCM), with a primary focus on oncology. Its lead program, Majiazi Capsule, is a Class 1.3 innovative drug currently undergoing Phase Ia clinical trials for the treatment of advanced solid tumors in patients who have failed standard therapies. The company leverages traditional botanical knowledge combined with modern clinical research to address unmet medical needs in cancer treatment.
- Therapeutic areas
- Oncology
- Modalities
- Botanical extractHerbal medicineSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on 成都马甲子生物科技.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 成都马甲子生物科技.